Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with or without irinotecan for metastatic colorectal cancer
ACTRN12612000901808Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) comparing Cetuximab monotherapy with Cetuximab + irinotecan (2 arms). Primary endpoint: 6-month progression-free survival benefit. Started Nov 2012; status: completed.
02
Drugs
cetuximabirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ACTRN12612000901808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000901808.